Jazz Pharma Says FDA Again Defied Orphan Drug Exclusivity
Jazz Pharma on Thursday asked a D.C. federal judge to block the U.S. Food and Drug Administration's "unlawful" approval of a rival narcolepsy treatment despite Jazz's exclusivity rights under the Orphan...To view the full article, register now.
Already a subscriber? Click here to view full article